Free Trial

SAB Biotherapeutics (SABS) Earnings Date, Estimates & Call Transcripts

SAB Biotherapeutics logo
$3.42 +0.23 (+7.21%)
(As of 11/12/2024 ET)

SAB Biotherapeutics Latest Earnings Summary

Upcoming
Earnings Date
Mar. 27Estimated
Actual EPS
(Nov. 6)
-$1.12 Missed By -$0.05
Consensus EPS
(Nov. 6)
-$1.07

SAB Biotherapeutics issued Q3 2024 earnings on November 6, 2024, reporting an EPS of -$1.12, which missed analysts' consensus estimates of -$1.07 by $0.05. With a trailing EPS of $0.00, SAB Biotherapeutics' earnings are expected to grow next year, from ($3.64) to ($3.04) per share.

SABS Upcoming Earnings

SAB Biotherapeutics' next earnings date is estimated for Thursday, March 27, 2025, based off prior year's reporting schedules.

Get SAB Biotherapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

SABS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SABS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

SAB Biotherapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.98-$0.98-$0.98
Q2 20241-$1.02-$1.02-$1.02
Q3 20241-$1.09-$1.09-$1.09
Q4 20242-$1.30-$1.12-$1.21
FY 20245($4.39)($4.21)($4.30)

SAB Biotherapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
3/27/2025
(Estimated)
------- 
11/6/2024--$1.07-$1.12 -$0.05-$1.12$0.50M-
8/8/2024--$1.13-$0.79+$0.34-$0.79-$0.26M
5/20/2024Q1 2024-$0.98-$0.54+$0.44-$0.54-$0.95M
11/13/2023Q3 2023-$0.10-$0.10--$0.10-$1.27M
8/21/2023Q2 2023-$0.14-$0.14--$0.14-$0.09M
5/16/2023Q1 2023-$0.08-$0.15 -$0.07-$0.15$5.56M$0.58M
11/15/2022Q3 2022-$0.14-$0.16 -$0.02-$0.16-$3.59M

SAB Biotherapeutics Earnings - Frequently Asked Questions

SAB Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based off last year's report dates. Learn more on SABS's earnings history.

In the previous quarter, SAB Biotherapeutics (NASDAQ:SABS) missed the analysts' consensus estimate of ($1.07) by $0.05 with a reported earnings per share (EPS) of ($1.12). Learn more on analysts' earnings estimate vs. SABS's actual earnings.

SAB Biotherapeutics (NASDAQ:SABS) has a recorded annual revenue of $2.24 million.

SAB Biotherapeutics (NASDAQ:SABS) has a recorded net income of -$42.19 million. SABS has generated $0.00 earnings per share over the last four quarters.

SAB Biotherapeutics's earnings are expected to grow from ($3.64) per share to ($3.04) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:SABS) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners